Relationship between thiazolidinedione use and cardiovascular outcomes and all‐cause mortality among patients with diabetes: a time‐updated propensity analysis

Abstract

Our findings suggest that pioglitazone may have a more favorable risk profile when compared to rosiglitazone, arguing against a singular effect for TZDs on cardiovascular outcomes.